H1152
| Code | Size | Price |
|---|
| SYN-1221-M100 | 100 mg | Enquire |
Quantity:
| SYN-1221-M050 | 50 mg | Enquire |
Quantity:
| SYN-1221-M001 | 1 mg | £104.00 |
Quantity:
| SYN-1221-M005 | 5 mg | £233.00 |
Quantity:
| SYN-1221-M010 | 10 mg | £350.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
Short Term: +4°C, Long Term: +4°C
Documents
Further Information
Alternate Names/Synonyms:
(S)-4-Methyl-5-((2-methyl-1,4-diazepan-1-yl)sulfonyl)isoquinoline dihydrochloride; H1152
Appearance:
Solid.
CAS:
871543-07-6
EClass:
32160000
Form (Short):
liquid
Hazards:
H303, H317, H333
InChi:
InChI=1S/C16H21N3O2S.2ClH/c1-12-9-18-11-14-5-3-6-15(16(12)14)22(20,21)19-8-4-7-17-10-13(19)2;;/h3,5-6,9,11,13,17H,4,7-8,10H2,1-2H3;2*1H/t13-;;/m0./s1
InChiKey:
BFOPDSJOLUQULZ-GXKRWWSZSA-N
Long Description:
Chemical. CAS: 871543-07-6. Formula: C16H21N3O2S . 2HCl. MW: 319.4 . 72.9. H-1152 is a potent, specific, ATP-competitive and cell permeable ROCK inhibitor, with an IC50 of 12nM for ROCKII. H-1152 poorly inhibits PKA, PKC and myosin light chain kinase. Rho kinase (ROCK) activated by GTP-linked Rho phosphorylates targets that are involved in cytoskeletal remodelling, smooth muscle contraction and neuronal development.
Molecular Formula:
C16H21N3O2S . 2HCl
Molecular Weight:
319.4 . 72.9
Package Type:
Plastic Vial
Product Description:
H-1152 is a potent, specific, ATP-competitive and cell permeable ROCK inhibitor, with an IC50 of 12nM for ROCKII. H-1152 poorly inhibits PKA, PKC and myosin light chain kinase. Rho kinase (ROCK) activated by GTP-linked Rho phosphorylates targets that are involved in cytoskeletal remodelling, smooth muscle contraction and neuronal development.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway: Y. Sasaki, et al.; Pharmacol. Ther. 93, 225 (2002) | Development of specific Rho-kinase inhibitors and their clinical application: M. Tamura, et al.; Biochim. Biophys. Acta 1754, 245 (2005) | Proerectile effects of the rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine (H-1152) in the rat penis: C.E. Teixeira, et al.; J. Pharmacol. Exp. Ther. 315, 155 (2005) | H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse: H.L. Wang, et al.; Neuropharmacol. 70, 1 (2013)
Related Products
| Product Name | Product Code | Supplier | NU6102 | AG-CR1-0020 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Y-27632 . dihydrochloride | AG-CR1-3564 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Momelotinib | SYN-1035 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| GSK429286A | SYN-1071 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SR3677 | SYN-1083 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||